vs
CytomX Therapeutics, Inc.（CTMX）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
CytomX Therapeutics, Inc.的季度营收约是RIVERVIEW BANCORP INC的1.3倍（$18.7M vs $14.0M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -0.8%，领先10.6%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -25.7%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-15.8M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -15.9%）
CytomX Therapeutics是一家临床阶段生物技术公司，专注于创新癌症免疫疗法研发，依托专有的Probody技术平台开发仅在肿瘤微环境中激活的靶向疗法，可降低脱靶毒性，管线覆盖多种实体瘤适应症，还与全球头部药企合作推进相关治疗方案开发。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CTMX vs RVSB — 直观对比
营收规模更大
CTMX
是对方的1.3倍
$14.0M
营收增速更快
RVSB
高出36.1%
-25.7%
净利率更高
RVSB
高出10.6%
-0.8%
自由现金流更多
RVSB
多$15.0M
$-15.8M
两年增速更快
RVSB
近两年复合增速
-15.9%
损益表 — Q2 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $18.7M | $14.0M |
| 净利润 | $-154.0K | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | -6.9% | 12.4% |
| 净利率 | -0.8% | 9.8% |
| 营收同比 | -25.7% | 10.4% |
| 净利润同比 | 97.6% | 11.8% |
| 每股收益（稀释后） | — | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTMXRVSB
| Q4 25 | — | $14.0M | ||
| Q3 25 | — | $13.6M | ||
| Q2 25 | $18.7M | $13.3M | ||
| Q1 25 | $50.9M | $12.9M | ||
| Q4 24 | $38.1M | $12.7M | ||
| Q3 24 | $33.4M | $12.8M | ||
| Q2 24 | $25.1M | $12.2M | ||
| Q1 24 | $41.5M | $9.0M |
净利润CTMXRVSB
| Q4 25 | — | $1.4M | ||
| Q3 25 | — | $1.1M | ||
| Q2 25 | $-154.0K | $1.2M | ||
| Q1 25 | $23.5M | $1.1M | ||
| Q4 24 | $18.9M | $1.2M | ||
| Q3 24 | $5.7M | $1.6M | ||
| Q2 24 | $-6.5M | $966.0K | ||
| Q1 24 | $13.8M | $-3.0M |
营业利润率CTMXRVSB
| Q4 25 | — | 12.4% | ||
| Q3 25 | — | 10.2% | ||
| Q2 25 | -6.9% | 11.7% | ||
| Q1 25 | 44.4% | 11.3% | ||
| Q4 24 | 46.4% | 12.4% | ||
| Q3 24 | 12.3% | 15.5% | ||
| Q2 24 | -33.7% | 10.0% | ||
| Q1 24 | 28.1% | -47.5% |
净利率CTMXRVSB
| Q4 25 | — | 9.8% | ||
| Q3 25 | — | 8.1% | ||
| Q2 25 | -0.8% | 9.2% | ||
| Q1 25 | 46.2% | 8.9% | ||
| Q4 24 | 49.6% | 9.7% | ||
| Q3 24 | 17.2% | 12.2% | ||
| Q2 24 | -26.0% | 7.9% | ||
| Q1 24 | 33.3% | -34.7% |
每股收益（稀释后）CTMXRVSB
| Q4 25 | — | $0.07 | ||
| Q3 25 | — | $0.05 | ||
| Q2 25 | — | $0.06 | ||
| Q1 25 | — | $0.05 | ||
| Q4 24 | — | $0.06 | ||
| Q3 24 | — | $0.07 | ||
| Q2 24 | — | $0.05 | ||
| Q1 24 | — | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $49.0M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $119.9M | $164.2M |
| 总资产 | $175.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTMXRVSB
| Q4 25 | — | $28.6M | ||
| Q3 25 | — | $32.8M | ||
| Q2 25 | $49.0M | $34.2M | ||
| Q1 25 | $47.6M | $29.4M | ||
| Q4 24 | $38.1M | $25.3M | ||
| Q3 24 | $40.6M | $31.0M | ||
| Q2 24 | $43.2M | $27.8M | ||
| Q1 24 | $36.2M | $23.6M |
股东权益CTMXRVSB
| Q4 25 | — | $164.2M | ||
| Q3 25 | — | $163.5M | ||
| Q2 25 | $119.9M | $162.0M | ||
| Q1 25 | $25.0M | $160.0M | ||
| Q4 24 | $-456.0K | $158.3M | ||
| Q3 24 | $-23.5M | $160.8M | ||
| Q2 24 | $-31.2M | $155.9M | ||
| Q1 24 | $-31.7M | $155.6M |
总资产CTMXRVSB
| Q4 25 | — | $1.5B | ||
| Q3 25 | — | $1.5B | ||
| Q2 25 | $175.1M | $1.5B | ||
| Q1 25 | $98.5M | $1.5B | ||
| Q4 24 | $120.5M | $1.5B | ||
| Q3 24 | $139.0M | $1.5B | ||
| Q2 24 | $159.2M | $1.5B | ||
| Q1 24 | $184.7M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-15.8M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-15.8M | $-736.0K |
| 自由现金流率自由现金流/营收 | -84.6% | -5.2% |
| 资本支出强度资本支出/营收 | 0.1% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-77.7M | $20.4M |
8季度趋势，按日历期对齐
经营现金流CTMXRVSB
| Q4 25 | — | $-506.0K | ||
| Q3 25 | — | $16.8M | ||
| Q2 25 | $-15.8M | $-697.0K | ||
| Q1 25 | $-21.0M | $8.3M | ||
| Q4 24 | $-19.9M | $2.2M | ||
| Q3 24 | $-20.7M | $764.0K | ||
| Q2 24 | $-19.5M | $5.4M | ||
| Q1 24 | $-26.0M | $12.8M |
自由现金流CTMXRVSB
| Q4 25 | — | $-736.0K | ||
| Q3 25 | — | $16.4M | ||
| Q2 25 | $-15.8M | $-773.0K | ||
| Q1 25 | $-21.2M | $5.6M | ||
| Q4 24 | $-20.0M | $1.9M | ||
| Q3 24 | $-20.7M | $-1.4M | ||
| Q2 24 | $-19.6M | $5.3M | ||
| Q1 24 | $-26.2M | $7.1M |
自由现金流率CTMXRVSB
| Q4 25 | — | -5.2% | ||
| Q3 25 | — | 120.1% | ||
| Q2 25 | -84.6% | -5.8% | ||
| Q1 25 | -41.6% | 43.1% | ||
| Q4 24 | -52.5% | 15.0% | ||
| Q3 24 | -62.1% | -11.3% | ||
| Q2 24 | -78.2% | 43.7% | ||
| Q1 24 | -63.1% | 79.0% |
资本支出强度CTMXRVSB
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 2.9% | ||
| Q2 25 | 0.1% | 0.6% | ||
| Q1 25 | 0.2% | 21.0% | ||
| Q4 24 | 0.2% | 2.4% | ||
| Q3 24 | 0.1% | 17.3% | ||
| Q2 24 | 0.4% | 0.9% | ||
| Q1 24 | 0.3% | 62.0% |
现金转化率CTMXRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | -0.89× | 7.20× | ||
| Q4 24 | -1.05× | 1.79× | ||
| Q3 24 | -3.61× | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | -1.89× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RVSB
暂无分部数据
